News

Patient-reported symptoms — specifically those related to blood vessel, skin, and lung function — may be used to indicate changes in disease activity in people with systemic sclerosis (SSc), an Australian study suggests. The study, “Can patient-reported symptoms be used to measure disease activity in systemic…

Loss of muscle mass and strength — known as sarcopenia — may affect up to 55% of patients with systemic sclerosis (SSc), a study suggests. Moreover, sarcopenia was found to be associated with several clinical and nutritional parameters of disease severity. The study, “Sarcopenia in systemic sclerosis: the impact…

Levels of a pro-inflammatory signaling molecule, called interleukin (IL)-6, are significantly high in skin lesions and blood samples of patients with systemic sclerosis (SSc), especially among those with diffuse cutaneous SSc, a small Japanese study reports. The study, “IL-16 expression is increased in the skin and sera of…

Patients with scleroderma show more frequent and/or stronger immune responses against the human cytomegalovirus (HCMV), suggesting a role in disease development, according to new research. The findings also revealed a correlation between these viral responses and scleroderma-associated autoantibodies. The study, “A comprehensive analysis of antigen-specific antibody…

Systemic sclerosis (SSc) patients with elevated protein in their urine (proteinuria) who are using angiotensin-converting enzyme (ACE) inhibitors (ACEi) are at higher risk of developing scleroderma renal crisis (SRC), a retrospective study shows. The study, “Systemic sclerosis mediations and risk of scleroderma renal crisis,” was published in the…